Literature DB >> 798489

Renal prostaglandins and the regulation of blood pressure and sodium and water homeostasis.

J B Lee, R V Patak, B K Mookerjee.   

Abstract

In addition to its well known prohypertensive role in various states of experimental and human hypertension, the kidney has also been shown to exert an antihypertensive "endocrine" function. According to this hypothesis, certain forms of experimental and human hypertension might not solely be the result of an excess in the activity of such renal pressor systems as the renin-angiotensin system and the sympathetic nervous system, but might also result from an absolute or relative deficiency of intra-renal vasodilator antihypertensive factors which might allow pressor systems to act unopposed to produce peripheral arteriolar vasoconstriction and sustained hypertension. At least four factors have been characterized in the kidney of various animal species and man which might be responsible for such an antihypertensive function. These are (1) the renomedullary prostaglandins (PGs), (2) the renomedullary antihypertensive neutral lipid, (3) antirenin phospholipid and (4) the renal kinins. This review is restricted to an examination of the possibility that the vasodepressor renomedullary prostaglandins (PGA and/or PGE) may, at least in part, mediate the so-called antihypertensive function of the kidney and participate in the regulation of renal blood flow and natriuresis by physiologic antagonism of various renal vasoconstrictor stimuli such as the renal renin-angiotensin and the sympathetic nervous systems.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 798489     DOI: 10.1016/0002-9343(76)90893-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

Review 1.  Pathophysiology and pharmacokinetics following burn injury.

Authors:  P L Bonate
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 2.  Resistance to loop diuretics. Why it happens and what to do about it.

Authors:  D C Brater
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

3.  Pseudohypoaldosteronism. Response to long-term treatment with indomethacin.

Authors:  M Bommen; C G Brook
Journal:  Arch Dis Child       Date:  1982-09       Impact factor: 3.791

4.  Pharmacokinetics/pharmacodynamics of furosemide in man: a review.

Authors:  L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

5.  Antidiuretic action of intravenous and intracerebral pyrogen in conscious rabbits.

Authors:  B Kruk; J Sadowski
Journal:  J Physiol       Date:  1978-09       Impact factor: 5.182

6.  The impact of microsomal prostaglandin e synthase 1 on blood pressure is determined by genetic background.

Authors:  Carie S Facemire; Robert Griffiths; Laurent P Audoly; Beverly H Koller; Thomas M Coffman
Journal:  Hypertension       Date:  2010-01-11       Impact factor: 10.190

7.  Comparative study of the blood pressure effects of four different vegetable fats on young, spontaneously hypertensive rats.

Authors:  P Hoffmann; H U Block; J Beitz; C Taube; W Forster; P Wortha; P Singer; E Naumann; H Heine
Journal:  Lipids       Date:  1986-12       Impact factor: 1.880

8.  Experimental dissociation of the effects of prostaglandins on renal sodium and water reabsorption by cyclo-oxygenase inhibitors in the rat.

Authors:  E Bartoli; G F Branca; R Faedda; N A Olmeo; A Satta; G Soggia
Journal:  Br J Pharmacol       Date:  1982-07       Impact factor: 8.739

9.  Pseudohypoaldosteronism type 1: clinical features and management in infancy.

Authors:  N Amin; N S Alvi; J H Barth; H P Field; E Finlay; K Tyerman; S Frazer; G Savill; N P Wright; T Makaya; T Mushtaq
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2013-08-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.